Departamento de Ensaios Clinicos

Associacao Protectora dos Diabeticos de Portugal

Diabetes Mellitus

Type 2 Diabetes Mellitus

Coronary Artery Disease

Infarction

Heart Diseases

Coronary Disease

Myocardial Ischemia

Myocardial Infarction

Sulfonylurea

Evolocumab

Metformin

AC2993

AstraZeneca

Amgen

condition

allSponsorName

gender

Male

Female

overallStatus

Recruiting

Not yet recruiting

Active, not recruiting

Enrolling by invitation

Completed

Terminated

Withdrawn

Suspended

Unknown

type

Interventional

Observational

Expanded Access

phase

Early Phase 1

Phase 1

Phase 2

Phase 3

Phase 4

Not Applicable

funderTypes

Industry

Other U.S. Federal agency

All others

ageGroup

Child (birth-17)

Adult (18-64)

Older Adult (65+)

This study will assess the effect of lowering low-density lipoprotein cholesterol (LDL-C) with evolocumab on major cardiovascular events in adults without a prior myocardial infarction (MI) or stroke who are at high risk of a cardiovascular event.

Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke

Associacao Protectora dos Diabeticos de Portugal | Departamento de Ensaios Clinicos

Site insights

Work at this site?

Active trials

Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke (VESALIUS-CV)

Trial sponsors